Theranexus Logo

Theranexus

Clinical-stage biopharmaceutical company developing treatments for rare neurological disorders.

ALTHX | PA

Overview

Corporate Details

ISIN(s):
FR0013286259
LEI:
969500BFCV6IC7MFQP20
Country:
France
Address:
60 AVENUE ROCKEFELLER, 69008 LYON

Description

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-14 18:30
THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIA…
English 212.6 KB
2025-10-14 18:30
THX PHARMA (THERANEXUS) ET EXELTIS FRANCHISSENT UNE ÉTAPE MAJEURE VERS LA COMME…
French 186.1 KB
2025-09-29 18:30
Theranexus devient THX Pharma : une évolution stratégique vers la commercialisa…
French 211.7 KB
2025-09-29 18:30
Theranexus Becomes THX Pharma: A Strategic Evolution Toward the Commercializati…
English 209.9 KB
2025-05-13 18:00
THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION ANNOUNCE STRONG POSITIVE REAL-W…
English 391.8 KB
2025-05-13 18:00
THERANEXUS ET LA FONDATION BEYOND BATTEN DISEASE ANNONCENT DES DONNÉES EN VIE R…
French 352.9 KB
2025-04-29 19:05
URD 2024
French 10.6 MB
2025-04-29 19:00
THERANEXUS PUBLISHES ITS 2024 FULL-YEAR RESULTS, PRESENTS ITS PROGRESS REPORT A…
English 336.5 KB
2025-04-29 19:00
THERANEXUS PUBLIE SES RÉSULTATS ANNUELS 2024, FAIT LE POINT SUR SES ACTIVITÉS E…
French 297.3 KB
2025-03-06 18:00
MODIFICATION DU CONTRAT DE LIQUIDITÉ CONFIÉ À PORTZAMPARC
French 272.5 KB
2025-01-23 18:15
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2025
English 262.8 KB
2025-01-23 18:00
THERANEXUS PUBLIE SON AGENDA FINANCIER POUR L'EXERCICE 2025
French 254.5 KB
2025-01-16 18:00
Information mensuelle relative au nombre total de droits de vote et d'actions c…
French 168.8 KB
2025-01-09 18:00
THERANEXUS ANNOUNCES THE PUBLICATION OF ITS LETTER TO SHAREHOLDERS
English 179.9 KB
2025-01-09 18:00
THERANEXUS ANNONCE LA PUBLICATION DE SA LETTRE AUX ACTIONNAIRES
French 181.7 KB

Automate Your Workflow. Get a real-time feed of all Theranexus filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Theranexus

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Theranexus via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Advicenne Logo
A specialty pharmaceutical company developing treatments for rare renal diseases.
France
ALDVI
AegirBio AB Logo
A diagnostics company specializing in therapeutic drug monitoring for biological drugs.
Sweden
AEGIR
Aelis Farma Logo
Biopharmaceutical company developing CB1 receptor inhibitors for CNS disorders.
France
AELIS
AEON Biopharma, Inc. Logo
Clinical-stage company developing therapeutic applications for botulinum toxins.
United States of America
AEON
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics with integrated R&D and manufacturing.
Japan
2927
AGENUS INC Logo
A clinical-stage biotechnology company specializing in immuno-oncology therapies.
United States of America
AGEN
AGIOS PHARMACEUTICALS, INC. Logo
Biopharmaceutical company developing therapies for rare and genetically defined diseases.
United States of America
AGIO
AHN-GOOK PHARMACEUTICAL Co., Ltd. Logo
Develops and markets medicines, focusing on respiratory and cardiovascular treatments.
South Korea
001540
Akari Therapeutics Plc Logo
Develops next-gen antibody-drug conjugates using proprietary cancer-killing toxins.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
A biopharmaceutical company that develops and commercializes therapeutics for kidney disease.
United States of America
AKBA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.